The Wnt family member WNT2B is a secreted glycoprotein involved in critical signaling pathways regulating embryonic development, tissue homeostasis, and cellular processes like proliferation, differentiation, and polarity. As part of the evolutionarily conserved Wnt/β-catenin and non-canonical pathways, WNT2B binds to Frizzled receptors and co-receptors (e.g., LRP5/6), initiating downstream signaling cascades. It plays roles in organogenesis, particularly in the central nervous system, eye, lungs, and reproductive tissues. Dysregulation of WNT2B is implicated in cancers (e.g., colorectal, gastric), developmental disorders, and degenerative conditions.
WNT2B antibodies are immunological tools designed to detect and study the expression, localization, and function of the WNT2B protein. These antibodies, often validated in techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF), enable researchers to investigate WNT2B's involvement in normal physiology and disease mechanisms. For instance, they help identify aberrant WNT2B overexpression in tumors or loss in congenital defects. Specificity is typically confirmed using knockout controls or siRNA-mediated knockdown. Commercial WNT2B antibodies may target specific epitopes (e.g., N-terminal or C-terminal regions) and are available in polyclonal or monoclonal formats. Their applications extend to developmental biology, cancer research, and regenerative medicine, providing insights into therapeutic targeting of Wnt-related pathologies. Proper validation remains essential to minimize cross-reactivity with homologous Wnt proteins like WNT2.